This online shop is using cookies to give you the best shopping experience. Thereby for example the session information or language setting are stored on your computer. Without cookies the range of the online shop's functionality is limited.
If you don't agree, please click here.
established from the peripheral blood of a 63-year-old woman with B-prolymphocytic leukemia (B-PLL) at diagnosis; recent molecular biological characterization assigned this cell line to the entity "mantle cell lymphoma" (MCL); cell line was established by EBV-transformation during treatment with phorbol ester TPA; cells were described in the literature to have immunoglobulin light chain restriction (lambda) and to carry t(11;14) leading to IGH-CCND1 (BCL1) fusion gene and CCND1 activation. Exome and RNA sequence data are available (see Ref 18187 and
Exome sequence and RNA-Seq)
The cell line is positive for EBV (HHV-4) by PCR analysis. However, expression of immediate-early protein BZLF-1 and lately expressed capsid protein were negative by western blot and immunostaining, respectively, in untreated and phorbol ester / sodium butyrate stimulated cells. The infection was classified as latent infection without production of active viruses. A transmission of EBV during handling of the cells is unlikely and thus the cell line is categorized biosafety level 1. According to a recommendation of the German Central Committee for Biological Safety (ZKBS) the cells have to be handled under biosafety level 2 when the cells are used in genetic engineering projects.